Accolade vs Collective Health

Side-by-side comparison of model-estimated upside.

Accolade

-64%

est. 2Y upside i

Healthcare

Rank

#3746

Sector

Healthcare Technology

Est. Liquidity

~3Y

Data Quality

Data: High

The equity opportunity in Transcarent (post-Accolade acquisition) is risky, with an expected upside of 7% over a two-year horizon.

Last updated: March 10, 2026

Collective Health

-39%

est. 2Y upside i

HealthcareSeries D+

Rank

#3611

Sector

HealthTech

Est. Liquidity

~3Y

Data Quality

Data: Medium

Collective Health operates in a growing HealthTech market with $143M revenue, but faces high incumbent and competitive threats from established players like Aetna and well-funded rivals such as Accolade.

Last updated: March 10, 2026

Upside Comparison

Expected Upside

Accolade

-64%

Collective Health

-39%

Disclaimer: These rankings are AI-generated estimates and do not constitute financial or career advice. Always conduct your own due diligence.